← Back to Analyst Consensus 
LTGO Buy
Latigo Biotherapeutics, Inc.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 1, 2026 | Leerink Partners | initiate | — → Outperform | — | 50% |
| Sep 1, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| Sep 1, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
Price Target Trend
Sep 3, 2026 Latest: $52.25 Oct 22, 2026
EPS Estimates
+1y $-2.32
Lo: $-2.76 Hi: $-2.07
4 analysts 0y $-3.01
Lo: $-4.52 Hi: $-2.11
3 analysts 0q $-0.67
Lo: $-0.69 Hi: $-0.65
2 analysts +1q $-0.85
Lo: $-0.86 Hi: $-0.84
2 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days